autologous NK cell plus GD2 antibody for neuroblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Apr 2025: Trial registered, NCT06948994

The trials

NCT06948994: A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed/Refractory Neuroblastoma

State
Not started
Phase
Phase 1 and Phase 2
People
15 planned
Started
1 May 2025
Primary completion
30 Apr 2027
Arms
intervention arm
Results
None posted
  1. 29 Apr 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.